Abstract
In an attempt to further understand the biological significance of soluble IL-2 receptors (sIL-2R) in solid tumors, we have evaluated 160 cancer patients (breast: 40; lung: 66; colon: 18; stomach: 22; uterine cervix: 14) and 58 healthy subjects, as controls. Serum mean levels of sIL-2R, measured with an enzyme immunoassay, were significantly higher in cancer patients than in controls. Metastatic cancer patients showed significantly higher values than the non-metastatic ones; this difference was significant in all tumor histotypes, except small cell lung carcinoma. Moreover, in 15 patients in whom sIL-2R were evaluated either before or after radical surgery, a significant surgery-induced increase in sIL-R mean values was seen. Finally, the chemotherapy-induced rise in sIL-2R appeared to be associated with a lack of clinical response. These results seem to suggest that sIL-2R may be a marker of host biological response in patients with solid tumors, the significance of which needs further investigation.
| Original language | English |
|---|---|
| Pages (from-to) | 33-36 |
| Number of pages | 4 |
| Journal | European Journal of Cancer and Clinical Oncology |
| Volume | 26 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1990 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
The biological significance of soluble interleukin-2 receptors in solid tumors. / Lissoni, P.; Barni, S.; Rovelli, F.; Viviani, S.; Maestroni, G. J M; Conti, A.; Tancini, G.
In: European Journal of Cancer and Clinical Oncology, Vol. 26, No. 1, 1990, p. 33-36.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The biological significance of soluble interleukin-2 receptors in solid tumors
AU - Lissoni, P.
AU - Barni, S.
AU - Rovelli, F.
AU - Viviani, S.
AU - Maestroni, G. J M
AU - Conti, A.
AU - Tancini, G.
PY - 1990
Y1 - 1990
N2 - In an attempt to further understand the biological significance of soluble IL-2 receptors (sIL-2R) in solid tumors, we have evaluated 160 cancer patients (breast: 40; lung: 66; colon: 18; stomach: 22; uterine cervix: 14) and 58 healthy subjects, as controls. Serum mean levels of sIL-2R, measured with an enzyme immunoassay, were significantly higher in cancer patients than in controls. Metastatic cancer patients showed significantly higher values than the non-metastatic ones; this difference was significant in all tumor histotypes, except small cell lung carcinoma. Moreover, in 15 patients in whom sIL-2R were evaluated either before or after radical surgery, a significant surgery-induced increase in sIL-R mean values was seen. Finally, the chemotherapy-induced rise in sIL-2R appeared to be associated with a lack of clinical response. These results seem to suggest that sIL-2R may be a marker of host biological response in patients with solid tumors, the significance of which needs further investigation.
AB - In an attempt to further understand the biological significance of soluble IL-2 receptors (sIL-2R) in solid tumors, we have evaluated 160 cancer patients (breast: 40; lung: 66; colon: 18; stomach: 22; uterine cervix: 14) and 58 healthy subjects, as controls. Serum mean levels of sIL-2R, measured with an enzyme immunoassay, were significantly higher in cancer patients than in controls. Metastatic cancer patients showed significantly higher values than the non-metastatic ones; this difference was significant in all tumor histotypes, except small cell lung carcinoma. Moreover, in 15 patients in whom sIL-2R were evaluated either before or after radical surgery, a significant surgery-induced increase in sIL-R mean values was seen. Finally, the chemotherapy-induced rise in sIL-2R appeared to be associated with a lack of clinical response. These results seem to suggest that sIL-2R may be a marker of host biological response in patients with solid tumors, the significance of which needs further investigation.
UR - http://www.scopus.com/inward/record.url?scp=0025269441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025269441&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(90)90253-P
DO - 10.1016/0277-5379(90)90253-P
M3 - Article
VL - 26
SP - 33
EP - 36
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 1
ER -